Asana BioSciences

What Asana BioSciences does

Asana BioSciences is a clinical-stage biopharmaceutical company headquartered in Princeton, New Jersey, founded in 2014. The company operates as a privately held, for-profit entity with a lean structure of 1–10 employees, indicating an R&D-focused operating model typical of pre-commercial biotechnology firms. Its primary activity is the development of therapeutic drug candidates, though specific pipeline assets, indications, mechanisms of action, and development stage are not disclosed in the available data.

The company is backed by Tarsadia Investments, a private investment firm, which provided initial capital at founding. The single recorded funding round in 2014 is reported with a $0 value, suggesting that capital flows are likely channeled through parent or sponsor relationships rather than through publicly disclosed external rounds. There are no disclosed partnerships, licensing agreements, collaborations, or commercialization deals in the input, and no management team, scientific leadership, or advisory board members are named.

As a pre-revenue clinical-stage biopharma, Asana BioSciences' business model would conventionally rely on out-licensing of pipeline assets, partnership milestone payments, or eventual commercialization, but no such revenue mechanics are documented. The firm website (asanabiosciences.com) is listed but no technology, product, or operational details could be extracted from the input. Overall, the data supports a characterization of Asana BioSciences as a small, privately funded, clinical-stage therapeutic developer with significant information gaps across pipeline, leadership, and commercial dimensions.

Name

Asana BioSciences

Website

https://asanabiosciences.com

Company type

Private

Founded year

2014

Headcount range

1–10 employees

Short description

Asana BioSciences is a privately held, clinical-stage biopharmaceutical company founded in 2014 in Princeton, New Jersey, backed by Tarsadia Investments. It develops therapeutic drug candidates through a lean 1–10 employee R&D operating model.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Clinical-stage biopharmaceuticals
• Drug development
• Therapeutics pipeline
• Pharmaceutical R&D
• Biotech innovation

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Core offering

Asana BioSciences is a clinical-stage biopharmaceutical company developing novel therapeutic candidates. The company conducts early-stage drug discovery, preclinical research, and clinical development aimed at advancing treatments for unmet medical needs across various disease areas.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Expansion highlights1 record

Direct peers

• Karuna Therapeutics: Clinical-stage CNS biopharma acquired by Bristol-Myers Squibb in 2024 after advancing a clinical-stage CNS asset. Comparable clinical-stage biotech with similar operating profile and a clean example of the strategic exit pathway for assets of this type.
• Axsome Therapeutics: Clinical-stage CNS-focused biopharmaceutical company that advanced small-molecule candidates through approval. Highly comparable in scale, therapeutic category (neuroscience/pain), and clinical-stage operating profile prior to commercialization.
• Intra-Cellular Therapies: Clinical-stage to commercial biopharmaceutical company developing small-molecule therapies for CNS and other indications. Closely comparable clinical-stage biotech with a similar lean model and late-stage asset profile, providing a like-for-like benchmark for valuation and pipeline structure.

Broad incumbents

• Pfizer: Large diversified pharmaceutical company with significant small-molecule R&D presence in the Princeton/New Jersey corridor. Represents a likely acquirer profile and ecosystem counterparty for a clinical-stage biotech in the same geography.
• Bristol-Myers Squibb: Major pharma headquartered in the Princeton/New Jersey corridor with a track record of acquiring clinical-stage CNS and immunology biotechs (e.g., Karuna, Celgene). A natural strategic counterparty for clinical-stage assets in the region.
• Johnson & Johnson Innovative Medicine: Large pharma with a New Jersey R&D footprint and active acquirer of clinical-stage biotechs across immunology, oncology, and neuroscience. Comparable as a broad incumbent and likely strategic exit partner.
• ACADIA Pharmaceuticals: Commercial-stage CNS biopharma with approved products, providing a benchmark for what a successful clinical-stage CNS-focused biotech can become. Broader incumbent with overlapping therapeutic categories.

Others

• Tarsadia Investments portfolio companies: Asana is backed by Tarsadia Investments; other Tarsadia healthcare portfolio companies are operationally and structurally comparable in terms of sponsor support, governance, and capital trajectory.
• Charles River Laboratories: Major CRO providing preclinical and clinical development services commonly used by clinical-stage biotechs. Relevant ecosystem participant and likely operational counterparty for a lean clinical-stage biotech like Asana.

Emerging players

• Ventyx Biosciences: Clinical-stage immunology and inflammation biopharmaceutical company developing small-molecule and biologic candidates. Comparable in being a small, clinical-stage, sponsor-backed biotech with similar burn dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asana BioSciences